Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Pyrrolidinones"" wg kryterium: Temat


Tytuł :
Bonded occlusal bite raisers for Class II malocclusion.
Autorzy :
Jain S; Indore, Madhya Pradesh, India.
Bunkar AK; Indore, Madhya Pradesh, India.
Kuriakose M; Indore, Madhya Pradesh, India.
Pokaż więcej
Źródło :
American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics [Am J Orthod Dentofacial Orthop] 2021 Apr; Vol. 159 (4), pp. 408-409.
Typ publikacji :
Letter; Comment
MeSH Terms :
Malocclusion, Angle Class II*/therapy
Pyrrolidinones*
Dental Occlusion ; Humans
Opinia redakcyjna
Tytuł :
First-in-Human Evaluation of F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A.
Autorzy :
Naganawa M; Yale University PET Center, New Haven, Connecticut .
Li S; Yale University PET Center, New Haven, Connecticut.
Nabulsi N; Yale University PET Center, New Haven, Connecticut.
Henry S; Yale University PET Center, New Haven, Connecticut.
Zheng MQ; Yale University PET Center, New Haven, Connecticut.
Pracitto R; Yale University PET Center, New Haven, Connecticut.
Cai Z; Yale University PET Center, New Haven, Connecticut.
Gao H; Yale University PET Center, New Haven, Connecticut.
Kapinos M; Yale University PET Center, New Haven, Connecticut.
Labaree D; Yale University PET Center, New Haven, Connecticut.
Matuskey D; Yale University PET Center, New Haven, Connecticut.
Huang Y; Yale University PET Center, New Haven, Connecticut.
Carson RE; Yale University PET Center, New Haven, Connecticut.
Pokaż więcej
Źródło :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Apr; Vol. 62 (4), pp. 561-567. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
GPI-Linked Proteins/*metabolism
Positron-Emission Tomography/*methods
Pyridines/*metabolism
Pyrrolidinones/*metabolism
Synaptic Vesicles/*metabolism
Adult ; Female ; Healthy Volunteers ; Humans ; Ligands ; Male ; Positron-Emission Tomography/adverse effects ; Pyridines/adverse effects ; Pyrrolidinones/adverse effects ; Safety
Czasopismo naukowe
Tytuł :
Simplified Quantification of C-UCB-J PET Evaluated in a Large Human Cohort.
Autorzy :
Naganawa M; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut .
Gallezot JD; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Finnema SJ; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Matuskey D; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.; Department of Psychiatry, Yale University, New Haven, Connecticut; and.; Department of Neurology, Yale University, New Haven, Connecticut.
Mecca A; Department of Psychiatry, Yale University, New Haven, Connecticut; and.
Nabulsi NB; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Labaree D; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Ropchan J; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Malison RT; Department of Psychiatry, Yale University, New Haven, Connecticut; and.
D'Souza DC; Department of Psychiatry, Yale University, New Haven, Connecticut; and.
Esterlis I; Department of Psychiatry, Yale University, New Haven, Connecticut; and.
Detyniecki K; Department of Neurology, Yale University, New Haven, Connecticut.
van Dyck CH; Department of Psychiatry, Yale University, New Haven, Connecticut; and.
Huang Y; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Carson RE; PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
Pokaż więcej
Źródło :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Mar; Vol. 62 (3), pp. 418-421. Date of Electronic Publication: 2020 Jul 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Image Processing, Computer-Assisted*
Positron-Emission Tomography*
Pyridines*
Pyrrolidinones*
Case-Control Studies ; Female ; Humans ; Male ; Mental Disorders/diagnostic imaging ; Middle Aged
Czasopismo naukowe
Tytuł :
Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
Autorzy :
Stephen L; Epilepsy Unit, West Glasgow Ambulatory Care Hospital, Scotland, United Kingdom. Electronic address: .
Brodie MJ; University of Glasgow, Glasgow, Scotland, United Kingdom.
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2021 Mar; Vol. 116, pp. 107746. Date of Electronic Publication: 2021 Jan 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticonvulsants*/therapeutic use
Pyrrolidinones*/therapeutic use
Adolescent ; Adult ; Child ; Europe ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Alkyl pyrrolidone solvents N-methyl-2-pyrrolidone (NMP) and N-ethyl-2-pyrrolidone (NEP) in urine of children and adolescents in Germany - human biomonitoring results of the German Environmental Survey 2014-2017 (GerESV).
Autorzy :
Schmied-Tobies MIH; German Environment Agency (UBA), Berlin, Germany.
Murawski A; German Environment Agency (UBA), Berlin, Germany. Electronic address: .
Rucic E; German Environment Agency (UBA), Berlin, Germany.
Schwedler G; German Environment Agency (UBA), Berlin, Germany.
Bury D; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
Kasper-Sonnenberg M; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
Koslitz S; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
Koch HM; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
Brüning T; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
Kolossa-Gehring M; German Environment Agency (UBA), Berlin, Germany.
Pokaż więcej
Źródło :
Environment international [Environ Int] 2021 Jan; Vol. 146, pp. 106221. Date of Electronic Publication: 2020 Oct 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biological Monitoring*
Pyrrolidinones*/analysis
Adolescent ; Child ; Child, Preschool ; Environmental Monitoring ; Germany ; Humans ; Solvents/analysis
Czasopismo naukowe
Tytuł :
Response to Letter to the Editor "Intravenous brivaracetam and lorazepam for acute seizure control: Are they equally effective?"
Autorzy :
Szaflarski JP; University of Alabama at Birmingham, Department of Neurology, The UAB Epilepsy Center, 1719 6th Avenue South, CIRC 312, Birmingham, AL 35294, USA. Electronic address: .
Sadek A; Neurological Services of Orlando, 3849 Oakwater Circle, Orlando, FL 32806, USA. Electronic address: .
Greve B; UCB Pharma, Alfred-Nobel-Straße 10, 40789 Monheim am Rhein, Germany. Electronic address: .
Williams P; UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: .
Varner JA; UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: .
Moseley BD; University of Cincinnati, 260 Stetson Street, Suite 2300, Cincinnati, OH 45267-0525, USA. Electronic address: .
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2020 Dec; Vol. 113, pp. 107512. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji :
Letter; Comment
MeSH Terms :
Lorazepam*/therapeutic use
Pyrrolidinones*/therapeutic use
Administration, Intravenous ; Humans ; Seizures/drug therapy
Opinia redakcyjna
Tytuł :
Intravenous brivaracetam and lorazepam for acute seizure control: Are they equally effective?
Autorzy :
Panda PK; All India Institute of Medical Sciences, Pediatrics, Rishikesh, India.
Saini K; All India Institute of Medical Sciences, Pediatrics, Rishikesh, India.
Sharawat IK; All India Institute of Medical Sciences, Pediatrics, Rishikesh, India. Electronic address: .
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2020 Dec; Vol. 113, pp. 107481. Date of Electronic Publication: 2020 Sep 28.
Typ publikacji :
Letter; Comment
MeSH Terms :
Lorazepam*/therapeutic use
Pyrrolidinones*
Humans ; Seizures/drug therapy
Opinia redakcyjna
Tytuł :
Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations.
Autorzy :
de Biase S; Neurology Unit, Ospedale dell'Angelo , Venezia-Mestre, Italy.
Gigli GL; Neurology Unit, Department of Neurosciences, University Hospital of Udine , Udine, Italy.; Department of Mathematics, Informatics and Physics (DMIF), University of Udine , Udine, Italy.
Valente M; Neurology Unit, Department of Neurosciences, University Hospital of Udine , Udine, Italy.; Department of Medical Area (DAME), University of Udine , Udine, Italy.
Pokaż więcej
Źródło :
Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2020 Oct; Vol. 16 (10), pp. 853-863. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Anticonvulsants/*administration & dosage
Epilepsies, Partial/*drug therapy
Pyrrolidinones/*administration & dosage
Animals ; Anticonvulsants/pharmacokinetics ; Anticonvulsants/pharmacology ; Drug Interactions ; Epilepsies, Partial/physiopathology ; Humans ; Pyrrolidinones/pharmacokinetics ; Pyrrolidinones/pharmacology ; Status Epilepticus/drug therapy ; Status Epilepticus/physiopathology
Czasopismo naukowe
Tytuł :
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Autorzy :
Asahina Y; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Wurtz NR; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Arakawa K; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Carson N; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Fujii K; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Fukuchi K; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Garcia R; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Hsu MY; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Ishiyama J; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Ito B; Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Kick E; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Lupisella J; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Matsushima S; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Ohata K; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Ostrowski J; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Saito Y; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Tsuda K; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Villarreal F; Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Yamada H; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Yamaoka T; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Wexler R; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Gordon D; Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
Kohno Y; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Sep 10; Vol. 63 (17), pp. 9003-9019. Date of Electronic Publication: 2020 May 24.
Typ publikacji :
Journal Article
MeSH Terms :
Pyrrolidinones/*chemistry
Receptors, Formyl Peptide/*agonists
Receptors, Lipoxin/*agonists
Animals ; Chemotaxis/drug effects ; Disease Models, Animal ; Drug Evaluation, Preclinical ; HEK293 Cells ; Heart Failure/pathology ; Heart Failure/prevention & control ; Humans ; Macrophages/cytology ; Macrophages/immunology ; Macrophages/metabolism ; Mice ; Microsomes, Liver/metabolism ; Neutrophils/cytology ; Neutrophils/physiology ; Phagocytosis/drug effects ; Pyrrolidinones/metabolism ; Pyrrolidinones/pharmacology ; Pyrrolidinones/therapeutic use ; Receptors, Formyl Peptide/genetics ; Receptors, Formyl Peptide/metabolism ; Receptors, Lipoxin/genetics ; Receptors, Lipoxin/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
N -Ethyl-2-Pyrrolidinone-Substituted Flavan-3-Ols with Anti-inflammatory Activity in Lipopolysaccharide-Stimulated Macrophages Are Storage-Related Marker Compounds for Green Tea.
Autorzy :
Dai W; Key Laboratory of Tea Biology and Resources Utilization, Ministry of Agriculture, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, Zhejiang 310008, People's Republic of China.
Lou N; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, People's Republic of China.; College of Integrative Medicine, Dalian Medical University, Dalian, Liaoning 116044, People's Republic of China.
Xie D; Key Laboratory of Tea Biology and Resources Utilization, Ministry of Agriculture, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, Zhejiang 310008, People's Republic of China.
Hu Z; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, People's Republic of China.
Song H; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, People's Republic of China.; College of Integrative Medicine, Dalian Medical University, Dalian, Liaoning 116044, People's Republic of China.
Lu M; Agilent Technologies (China) Limited, Beijing 100102, People's Republic of China.
Shang D; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, People's Republic of China.; College of Integrative Medicine, Dalian Medical University, Dalian, Liaoning 116044, People's Republic of China.
Wu W; Key Laboratory of Tea Biology and Resources Utilization, Ministry of Agriculture, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, Zhejiang 310008, People's Republic of China.
Peng J; Key Laboratory of Tea Biology and Resources Utilization, Ministry of Agriculture, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, Zhejiang 310008, People's Republic of China.
Yin P; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, People's Republic of China.; College of Integrative Medicine, Dalian Medical University, Dalian, Liaoning 116044, People's Republic of China.
Lin Z; Key Laboratory of Tea Biology and Resources Utilization, Ministry of Agriculture, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, Zhejiang 310008, People's Republic of China.
Pokaż więcej
Źródło :
Journal of agricultural and food chemistry [J Agric Food Chem] 2020 Oct 28; Vol. 68 (43), pp. 12164-12172. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*pharmacology
Camellia sinensis/*chemistry
Flavonoids/*pharmacology
Macrophages/*drug effects
Plant Extracts/*pharmacology
Pyrrolidinones/*pharmacology
Animals ; Anti-Inflammatory Agents/chemistry ; Flavonoids/chemistry ; Food Storage ; Lipopolysaccharides/immunology ; Macrophages/immunology ; Mice ; NF-kappa B/genetics ; NF-kappa B/immunology ; Plant Extracts/chemistry ; Plant Leaves ; Pyrrolidinones/chemistry ; RAW 264.7 Cells ; Time Factors
Czasopismo naukowe
Tytuł :
Reusable fibrous adsorbent prepared via Co-radiation induced graft polymerization for iodine adsorption.
Autorzy :
Ye F; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Huang C; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China; School of Petrochemical Engineering, Changzhou University, Changzhou, 213164, China.
Jiang X; Jining University, Qufu, 273155, China.
He W; Qilu Institute of Technology, Jinan, 250200, China.
Gao X; Qilu Institute of Technology, Jinan, 250200, China.
Ma L; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Ao J; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Xu L; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Wang Z; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Li Q; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Li J; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Ma H; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. Electronic address: .
Pokaż więcej
Źródło :
Ecotoxicology and environmental safety [Ecotoxicol Environ Saf] 2020 Oct 15; Vol. 203, pp. 111021. Date of Electronic Publication: 2020 Jul 22.
Typ publikacji :
Journal Article
MeSH Terms :
Gamma Rays*
Air Pollutants, Radioactive/*analysis
Green Chemistry Technology/*methods
Iodine/*analysis
Polypropylenes/*chemistry
Pyrrolidinones/*chemistry
Adsorption ; Humans ; Kinetics ; Polymerization ; Polypropylenes/radiation effects ; Pyrrolidinones/radiation effects ; Surface Properties
Czasopismo naukowe
Tytuł :
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
Autorzy :
Kudo M; Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Morimoto M; Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Moriguchi M; Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Izumi N; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Takayama T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Yoshiji H; Department of Gastroenterology, Nara Medical University, Nara, Japan.
Hino K; Department of Hepatology and Pancreatology, Kawasaki Medical School, Okayama, Japan.
Oikawa T; Department of Internal Medicine, Division of Hepatology, Iwate Medical University, Iwate, Japan.
Chiba T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Motomura K; Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan.
Kato J; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
Yasuchika K; Department of Surgery, Division of Hepatobiliary Pancreatic Surgery and Transplantation, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ido A; Department of Gastroenterology, Kagoshima University Medical and Dental Hospital, Kagoshima, Japan.
Sato T; R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.
Nakashima D; R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.
Ueshima K; Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tamura K; General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Furuse J; Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Oct; Vol. 111 (10), pp. 3759-3769. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Proto-Oncogene Proteins c-met/*genetics
Pyrrolidinones/*administration & dosage
Quinolines/*administration & dosage
Adult ; Aged ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/pathology ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Japan/epidemiology ; Liver Neoplasms/genetics ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Pyrrolidinones/adverse effects ; Quinolines/adverse effects
Czasopismo naukowe
Tytuł :
Time course of drug-related treatment-emergent adverse side effects of brivaracetam.
Autorzy :
Meador KJ; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: .
Laloyaux C; UCB Pharma, Brussels, Belgium. Electronic address: .
Elmoufti S; UCB Pharma, Raleigh, NC, USA. Electronic address: .
Gasalla T; UCB Pharma, Monheim am Rhein, Germany. Electronic address: .
Fishman J; UCB Pharma, Smyrna, GA, USA. Electronic address: .
Martin MS; UCB Pharma, Smyrna, GA, USA. Electronic address: .
Klein P; Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA. Electronic address: .
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2020 Oct; Vol. 111, pp. 107212. Date of Electronic Publication: 2020 Jun 14.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticonvulsants/*adverse effects
Clinical Trials, Phase III as Topic/*methods
Drug-Related Side Effects and Adverse Reactions/*diagnosis
Drug-Related Side Effects and Adverse Reactions/*epidemiology
Pyrrolidinones/*adverse effects
Adult ; Anticonvulsants/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Pyrrolidinones/therapeutic use ; Seizures/drug therapy ; Seizures/epidemiology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
Autorzy :
Liguori C; Epilepsy Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome.
Manfredi N; Epilepsy Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome.
Renna R; UOC Neurologia, A.O.R.N. 'A. Cardarelli', Naples.
Izzi F; Epilepsy Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome.
Pagliuca M; UOC Neurologia, A.O.R.N. 'A. Cardarelli', Naples.
Pagliuca F; Clinica Neurologica, Università 'L. Vanvitelli', Naples.
Mercuri NB; Epilepsy Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome,, IRCCS Fondazione Santa Lucia, Rome, Italy.
Fabio P; Epilepsy Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome.
Pokaż więcej
Źródło :
Epileptic disorders : international epilepsy journal with videotape [Epileptic Disord] 2020 Jun 01; Vol. 22 (3), pp. 309-316.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Outcome Assessment, Health Care*
Anticonvulsants/*pharmacology
Pyridones/*pharmacology
Pyrrolidinones/*pharmacology
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Anticonvulsants/administration & dosage ; Anticonvulsants/adverse effects ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Pyridones/administration & dosage ; Pyridones/adverse effects ; Pyrrolidinones/administration & dosage ; Pyrrolidinones/adverse effects ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity.
Autorzy :
Szaflarski JP; University of Alabama at Birmingham, Department of Neurology and the UAB Epilepsy Center, 1719 6th Avenue South, CIRC 312, Birmingham, AL 35294, USA. Electronic address: .
Sadek A; Neurological Services of Orlando, 3849 Oakwater Cir, Orlando, FL 32806, USA. Electronic address: .
Greve B; UCB Pharma, Alfred-Nobel-Straße 10, 40789 Monheim am Rhein, Germany. Electronic address: .
Williams P; UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: .
Varner JA; UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: .
Moseley BD; University of Cincinnati, 260 Stetson Street, Suite 2300, Cincinnati, OH 45267-0525, USA. Electronic address: .
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2020 Aug; Vol. 109, pp. 107127. Date of Electronic Publication: 2020 May 14.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticonvulsants/*administration & dosage
Epilepsy/*drug therapy
Lorazepam/*administration & dosage
Pyrrolidinones/*administration & dosage
Seizures/*drug therapy
Administration, Intravenous ; Adolescent ; Adult ; Aged ; Anticonvulsants/adverse effects ; Dizziness/chemically induced ; Double-Blind Method ; Electroencephalography/drug effects ; Electroencephalography/methods ; Epilepsy/diagnosis ; Female ; Humans ; Lorazepam/adverse effects ; Male ; Middle Aged ; Proof of Concept Study ; Pyrrolidinones/adverse effects ; Seizures/diagnosis ; Sleepiness ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials.
Autorzy :
Deng H; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Jiangxi Medical College, Nanchang University.
Wang L; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University.; Jiangxi Medical College, Nanchang University.
Chen X; Jiangxi Medical College, Nanchang University.; Department of Oncology, The second affiliated hospital of Nanchang University, Nanchang, China.
Zhang S; Jiangxi Medical College, Nanchang University.; Department of Oncology, The second affiliated hospital of Nanchang University, Nanchang, China.
Yi F; Department of Oncology, The second affiliated hospital of Nanchang University, Nanchang, China.
Wei Y; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University.
Zhang W; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jun 19; Vol. 99 (25), pp. e20596.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Erlotinib Hydrochloride/*administration & dosage
Lung Neoplasms/*drug therapy
Pyrrolidinones/*administration & dosage
Quinolines/*administration & dosage
Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Erlotinib Hydrochloride/adverse effects ; Humans ; Progression-Free Survival ; Pyrrolidinones/adverse effects ; Quinolines/adverse effects ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Clinical experience with brivaracetam in a series of 46 children.
Autorzy :
Visa-Reñé N; Paediatric Department, Hospital Universitari Arnau de Vilanova [Arnau de Vilanova University Hospital], Lleida, Spain. Electronic address: .
Raspall-Chaure M; Paediatric Neurology Department, Hospital Materno-Infantil Vall d'Hebron [Vall d'Hebron Maternity-Neonatal Hospital], Barcelona, Spain.
Paredes-Carmona F; Paediatric Department, Hospital Universitari Arnau de Vilanova [Arnau de Vilanova University Hospital], Lleida, Spain.
Coromina JS; Paediatric Neurology Department, Hospital Materno-Infantil Vall d'Hebron [Vall d'Hebron Maternity-Neonatal Hospital], Barcelona, Spain.
Macaya-Ruiz A; Paediatric Neurology Department, Hospital Materno-Infantil Vall d'Hebron [Vall d'Hebron Maternity-Neonatal Hospital], Barcelona, Spain.
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2020 Jun; Vol. 107, pp. 107067. Date of Electronic Publication: 2020 Apr 14.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anticonvulsants/*therapeutic use
Epilepsies, Partial/*diagnosis
Epilepsies, Partial/*drug therapy
Epilepsy, Generalized/*diagnosis
Epilepsy, Generalized/*drug therapy
Pyrrolidinones/*therapeutic use
Adolescent ; Anticonvulsants/adverse effects ; Child ; Female ; Humans ; Irritable Mood/drug effects ; Irritable Mood/physiology ; Levetiracetam/adverse effects ; Levetiracetam/therapeutic use ; Male ; Pyrrolidinones/adverse effects ; Retrospective Studies ; Treatment Outcome ; Wakefulness/drug effects ; Wakefulness/physiology
Czasopismo naukowe
Tytuł :
Development and Validation of an UHPLC-MS/MS Assay for the Therapeutic Monitoring of Brivaracetam Plasma Concentrations in Patients with Epilepsy.
Autorzy :
Mohamed S; IRCCS-Istituto delle Scienze Neurologiche di Bologna; and.
Riva R; IRCCS-Istituto delle Scienze Neurologiche di Bologna; and.; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Contin M; IRCCS-Istituto delle Scienze Neurologiche di Bologna; and.; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Pokaż więcej
Źródło :
Therapeutic drug monitoring [Ther Drug Monit] 2020 Jun; Vol. 42 (3), pp. 445-451.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticonvulsants/*blood
Chromatography, High Pressure Liquid/*methods
Drug Monitoring/*methods
Epilepsy/*drug therapy
Pyrrolidinones/*blood
Tandem Mass Spectrometry/*methods
Anticonvulsants/therapeutic use ; Chromatography, High Pressure Liquid/standards ; Drug Monitoring/standards ; Humans ; Pyrrolidinones/therapeutic use ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
The race for antiviral drugs to beat COVID - and the next pandemic.
Autorzy :
Dolgin E
Pokaż więcej
Źródło :
Nature [Nature] 2021 Apr; Vol. 592 (7854), pp. 340-343.
Typ publikacji :
Journal Article
MeSH Terms :
Pandemics*
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Drug Development/*trends
Adenosine Monophosphate/administration & dosage ; Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/administration & dosage ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Animals ; Antiviral Agents/pharmacology ; Birds/virology ; COVID-19/virology ; Clinical Trials as Topic ; Coronavirus/classification ; Coronavirus/drug effects ; Coronavirus Infections/epidemiology ; Cytidine/administration & dosage ; Cytidine/analogs & derivatives ; Cytidine/chemical synthesis ; Cytidine/therapeutic use ; Drug Industry/trends ; Europe ; Humans ; Hydroxylamines/administration & dosage ; Hydroxylamines/chemical synthesis ; Hydroxylamines/therapeutic use ; Indoles/administration & dosage ; Indoles/therapeutic use ; Influenza, Human/drug therapy ; Influenza, Human/virology ; Leucine/administration & dosage ; Leucine/therapeutic use ; Orthomyxoviridae/drug effects ; Pyrrolidinones/administration & dosage ; Pyrrolidinones/therapeutic use ; Severe Acute Respiratory Syndrome/drug therapy ; Severe Acute Respiratory Syndrome/epidemiology ; Strategic Stockpile ; United States
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Autorzy :
Yang KS; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Ma XR; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Ma Y; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Alugubelli YR; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Scott DA; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Vatansever EC; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Drelich AK; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Sankaran B; Molecular Biophysics and Integrated Bioimaging Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Geng ZZ; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Blankenship LR; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Ward HE; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Sheng YJ; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Hsu JC; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Kratch KC; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Zhao B; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Hayatshahi HS; Department of Pharmaceutical Sciences, UNT Health Science Center, Fort Worth, TX 76107, USA.
Liu J; Department of Pharmaceutical Sciences, UNT Health Science Center, Fort Worth, TX 76107, USA.
Li P; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Fierke CA; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Tseng CK; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Xu S; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Liu WR; Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.; Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M University, College Station, TX 77843, USA.; Institute of Biosciences and Technology and Department of Translational Medical Sciences College of Medicine, Texas A&M University, Houston, TX 77030, USA.
Pokaż więcej
Źródło :
ChemMedChem [ChemMedChem] 2021 Mar 18; Vol. 16 (6), pp. 942-948. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*pharmacology
Coronavirus 3C Proteases/*antagonists & inhibitors
Cysteine Proteinase Inhibitors/*pharmacology
SARS-CoV-2/*drug effects
A549 Cells ; Alanine/analogs & derivatives ; Alanine/metabolism ; Alanine/pharmacology ; Animals ; Antiviral Agents/chemical synthesis ; Antiviral Agents/metabolism ; Catalytic Domain ; Chlorocebus aethiops ; Coronavirus 3C Proteases/chemistry ; Coronavirus 3C Proteases/metabolism ; Cysteine/chemistry ; Cysteine Proteinase Inhibitors/chemical synthesis ; Cysteine Proteinase Inhibitors/metabolism ; Humans ; Microbial Sensitivity Tests ; Protein Binding ; Pyrrolidinones/chemical synthesis ; Pyrrolidinones/metabolism ; Pyrrolidinones/pharmacology ; SARS-CoV-2/enzymology ; Vero Cells
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies